IMMUNOMEDICS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2017 12 months to Jun 30, 2018	FY2016 12 months to Jun 30, 2017	FY2015 12 months to Jun 30, 2016	FY2014 12 months to Jun 30, 2015
Product sales
License fee and other revenues
Research and development
Revenues
Product sales
License fee and other revenues
Research and development
Total revenues
Costs and expenses:
Costs of goods sold
Research and development
Sales and marketing
General and administrative
Total costs and expenses
Operating loss
Changes in fair market value of warrant liabilities
Warrant related expenses
Interest expense
Interest and other income
Loss on induced exchanges of debt
Other financing expenses
Insurance reimbursement
Foreign currency transaction gain, net
Loss before income tax
Income tax expense
Net loss
Net loss attributable to noncontrolling interest
Net loss attributable to Immunomedics, Inc. stockholders
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)
Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments
Unrealized gain (loss) on securities available for sale
Other comprehensive income (loss), net of tax:
Comprehensive loss
Comprehensive loss attributable to noncontrolling interest
Comprehensive loss attributable to Immunomedics, Inc. stockholders

Comments